Anti-CD40 monoclonal antibody
Anti-CD40 monoclonal antibody
复制标题
DOI：
10.1080/10428190500085255
复制
发表时间：
2005-08-01
影响因子：
2.6
通讯作者：
Illidge, T
中科院分区：
文献类型：
--
作者：
Geldart, T;Illidge, T
CD40 与其天然配体 CD154（CD40 配体）之间正常的双向相互作用对于 T 细胞依赖性体液免疫反应和细胞毒性 T 细胞反应的产生至关重要。 CD40 在多种血液和上皮恶性肿瘤中表达。针对 CD40 的单克隆抗体的开发可以通过多种机制有效靶向恶性细胞，包括募集免疫效应机制，如补体依赖性细胞毒性和抗体依赖性细胞毒性、对肿瘤细胞的直接抗增殖作用，以及重要的是通过激活肿瘤靶向细胞毒性。这篇综述提供了早期临床试验数据的背景，这些数据现在开始出现，用于这种可能令人兴奋的新治疗方法。
Normal, bi-directional interactions between CD40 and its natural ligand CD154 (CD40 ligand) are central to the generation of both T cell-dependent, humoral immune responses and cytotoxic T-cell responses. CD40 is expressed on a broad range of hematological and epithelial malignancies. The development of monoclonal antibodies directed against CD40 allows effective targeting of malignant cells through multiple mechanisms that include the recruitment of immune effector mechanisms such as complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity, direct anti-proliferative effects on neoplastic cells and, importantly, by the activation of tumor-targeted cellular cytotoxicity. This review provides the background to the early clinical trial data that are now beginning to emerge for this potentially exciting new treatment approach.